Peptide derivatives and pharmaceutical compositions containing same

Claim 2

Compounds of the formula: A-L-B-D-Lys-L-Phe-Gly-(L or D)Lys-L-Pro-L-Val-Gly-L-Lys-L-Lys-X and their functional derivatives, wherein: A is an N-terminal chain prolongation selected from the group consisting of: (1) hydrogen, and (2) the N-acyl radicals derived from: (a) alkyl carboxylic acids having from one to about six carbon atoms, (b) aralkyl carboxylic acids having from seven to about ten carbon atoms, (c) amino acids selected from the group consisting of Met, Met(→ O), Met (→ O 2 ), Glu, Ser, His, Phe, Arg, Lys, Trp, Gly, Val, Leu, Ala, Ileu, β-Ala, (α-Me) Ala, Pro, Tyr, and Thr, (d) peptides comprising two or three α-amino acids, (e) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said amino acids, and (f) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said peptides, wherein the alkyl moiety in (e) and (f) has from one to about six carbon atoms, and wherein the aralkyl moiety in (e) and (f) has from seven to about ten carbon atoms; B is an amino acid residue selected from the group consisting of Phe, Trp, Tyr and --NH--CHR 1 --CO--, wherein R 1 is hydrogen or alkyl from one to about six carbon atoms; and X is a member selected from the group consisting of hydroxy, esterified hydroxy radicals of from one to eighteen carbon atoms, unsubstituted amino radicals, and substituted amino radicals selected from the group consisting of mono-alkyl (one to six carbons) amino, dialkyl-(one to six carbons) amino radicals, and radicals derived from amino acids or peptides having the sequence 17, 17-18, 17-19, up to and including 17-24 of the ACTH molcule, or a C-terminal ester o amide thereof, with the proviso that Arg may be replaced by Lys.

Claim 3

Compounds as recited in claim 1, wherein X is an unsubstituted amino radical.

Claim 4

Compounds as recited in claim 1, wherein A is a peptide comprising two or three amino acids selected from the group consisting of Met, Met (→ O), Met (→ O 2 ), Glu, Ser, His, Phe, Arg, Lys, Trp, Gly, Val, Leu, Ala, Ile, β-Ala, Ala, Tyr, and Thr.

Claim 5

Compounds as recited in claim 1, wherein B represents the amino acid residue Phe or Ala.

Claim 6

Compounds as recited in claim 1, wherein A is a radical selected from the group consisting of U, U-Q 1 , U-Q 2 -Q 1 , and Q 3 -Q 2 -Q 1 , wherein: U is selected from the group consisting of hydrogen, N-alkylcarbonyl of from one to about six carbons, and N-aralkylcarbonyl from seven to about ten carbon atoms; Q 1 is selected from the group amino-acid residues consisting of L-His, D-His, or NH-Z-CO, wherein Z is an unsubstituted, monohydroxy-substituted, or mono-amino substituted alkylene or alkylidene moiety of from one to about six carbon atoms; Q 2 is selected from the group of amino-acid residues consisting of L-Glu, D-Glu, L-Gln, D-Gln or -NH-Z-CO-; and Q 3 is selected from the group acid residues consisting of U-L-Met, U-L-Met(→ O), U-L-Met(→ O 2 ), U-D-Met, U-D-Met(→ O), U-D-Met(→ O 2 ), desamino-Met, desamino-Met(→ O), desamino-Met(→ O 2 ), and UNH-Z-CO-.

Claim 7

Compounds as recited in claim 5, wherein A represents the moiety Q 3 -Q 2 -Q 1 , wherein Q 1 , Q 2 and Q 3 have the meanings indicated in claim 5.

Claim 8

Compounds as recited in claim 1, wherein A is selected from the group consisting of H-Met-Glu-His, desamino-Met-Glu-His, H-Met-Ala-Ala and desamino-Met-Ala-Ala.

Claim 9

Compounds as recited in claim 1, wherein A is selected from the sulfoxides or sulfones of H-Met-Glu-His, desamino-Met-Glu-His, H-Met-Ala-Ala and desamino-Met-Ala-Ala.

Claim 10

Compounds as recited in claim 1, wherein the second lysine group is in its D-form.

Claim 11

The compound as recited in claim 9 wherein A is H-Met-Ala-Ala, B is Phe, and X is NH 2 , or an acid addition salt thereof.

Claim 12

The compound as recited in claim 9 wherein A is H-Met(→ O 2 )-Ala-Ala, B is Phe, and X is NH 2 , or an acid addition salt thereof.

Claim 13

The compound as recited in claim 9 wherein A is H-Met(→ O)-Ala-Ala, B is Phe, and X is NH 2 , or an acid addition salt thereof.

Claim 14

The compound as recited in claim 9 wherein A is H-Met(→ O 2 )-Glu-His, B is Phe, and X is NH 2 , or an acid addition salt thereof.

Claim 15

The compound as recited in claim 9 wherein A is H-Met(→ O 2 )-Ala-Ala, B is Ala, and X is NH 2 .

Claim 16

The compound as recited in claim 9 wherein A is desamino-Met(→ O 2 )-Ala-Ala, B is Phe, and X is NH 2 .

Claim 17

The compound as recited in claim 9 wherein A is desamino-Met(→ O)-Ala-Ala, B is Phe, and X is NH 2 .

Claim 18

The compound as recited in claim 9 wherein A is H-Met(→ O)-Glu-His, B is Phe, and X is NH 2 .

Claim 19

A pharmaceutical composition having conditioned flight inhibiting psychopharmacological properties comprising: (A) a pharmaceutically effective amount of a compound of the formula: A-L-B-D-Lys-L-Phe-Gly-(L or D)Lys-L-Pro-L-Val-Gly-L-Lys-L-Lys-X and their functional derivatives, wherein: A is an N-terminal chain prolongation selected from the group consisting of: (1) hydrogen, and (2) the N-acyl radicals derived from: (a) alkyl carboxylic acids having from seven to about six ten atoms, (b) aralkyl carboxylic acids having from one to about six carbon atoms, (c) amino acids selected from the group consisting of Met, Met (→ O), Met (→ O 2 ), Glu, Ser, His, Phe, Arg, Lys, Trp, Gly, Val, Leu, Ala, Ileu, β-Ala, (α-Me)Ala, Pro, Tyr, and Thr, (d) peptides comprising two or more α-amino acids, (e) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said amino acids, and (f) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said peptides, wherein the alkyl moiety in (e) and (f) has from one to about six carbon atoms, and wherein the aralkyl moiety in (e) and (f) has from seven to about ten carbon atoms; B is an amino acid residue selected from the group consisting of Phe, Trp, Tyr and --NH--CHR 1 --CO--, wherein R 1 is hydrogen or alkyl from one to about six carbon atoms; and X is a member selected from the group consisting of hydroxy, esterified hydroxy radicals of from one to eighteen carbon atoms, unsubstituted amino radicals, and substituted amino radicals selected from the group consisting of mono-alkyl (one to six carbon) amino, dialkyl-(one to six carbons) amino, and radicals, derived from amino acids or peptides having the sequence 17, 17-18, 17-19, up to and including 17-24 of the ACTH molecule, or a C-terminal ester or amide thereof, with the proviso that Arg may be replaced by Lys; or pharmaceutically acceptable and nontoxic functional derivative thereof; and (B) a pharmaceutically acceptable carrier therefor.

Claim 20

A pharmaceutical composition having conditioned flight inhibiting psychopharmacological properties comprising: (A) a pharmaceutically effective amount of a compound of the formula: A-L-B-D-Lys-L-Phe-Gly-(L or D)Lys-L-Pro-L-Val-Gly-L-Lys-L-Lys-X and their functional derivatives, wherein: A is an N-terminal chain prolongation selected from the group consisting of: (1) hydrogen, and (2) the N-acyl radicals derived from: (a) alkyl carboxylic acids having from seven to about six ten atoms, (b) aralkyl carboxylic acids having from one to about six carbon atoms, (c) amino acids selected from the group consisting of Met, Met (→ O), Met (→ O 2 ), Glu, Ser, His, Phe, Arg, Lys, Trp, Gly, Val, Leu, Ala, Ileu, β-Ala, (α-Me)Ala, Pro, Tyr, and Thr, (d) peptides comprising two or more α-amino acids, (e) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said amino acids, and (f) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of said peptides, wherein the alkyl moiety in (e) and (f) has from one to about six carbon atoms, and wherein the aralkyl moiety in (e) and (f) has from seven to about ten carbon atoms; B is an amino acid residue selected from the group consisting of Phe, Trp, Tyr and --NH--CHR 1 --CO--, wherein R 1 is hydrogen or alkyl from one to about six carbon atoms; and X is a member selected from the group consisting of hydroxy, esterified hydroxy radicals of from one to eighteen carbon atoms, unsubstituted amino radicals, and substituted amino radicals selected from the group consisting of mono-alkyl (one to six carbon) amino, dialkyl-(one to six carbons) amino, and radicals, derived from amino acids or peptides having the sequence 17, 17-18, 17-19, up to and including 17-24 of the ACTH molecule, or a C-terminal ester or amide thereof, with the proviso that Arg may be replaced by Lys; or pharmaceutically acceptable and nontoxic functional derivative thereof; and (B) a pharmaceutically acceptable carrier therefor.

Claim 21

A composition of matter as recited in claim 18 wherein B represents the amino-acid residue Phe or Ala.

Claim 22

A composition of matter as recited in claim 18, wherein X is an unsubstituted amino radical.

Claim 23

A composition of matter as recited in claim 18, wherein A is a radical selected from the group consisting of U, U-Q 1 ; U-Q 2 , and Q 3 -Q 2 -Q 1 , wherein: U is selected from the group consisting of hydrogen, N-alkylcarbonyl of from one to about six carbons, and N-aralkylcarbonyl from seven to about ten carbon atoms; Q 1 is selected from the group amino-acid residues consisting of L-His, D-His, or NH-Z-CO, wherein Z is an unsubstituted, monohydroxy substituted, or monoamino substituted alkylene or alkylidene moiety of from one to about six carbon atoms; Q 2 is selected from the group of amino-acid residues consisting of L-Glu, D-Glu, L-Gln, D-Gln or -NH-Z-CO-; and Q 3 is selected from the group acid residues consisting of U-L-Met, U-L-Met(→ O), U-L-Met(→ O 2 ), U-D-Met, U-D-Met(→ O), U-D-Met(→ O 2 ), desamino-Met, desamino-Met(→ O), desamino-Met(→ O 2 ), and UNH-Z-CO-.

Claim 24

Compounds as recited in claim 21, wherein A is the moiety Q 3 -Q 2 -Q 1 , wherein Q 1 , Q 2 and Q 3 have the meanings indicated in claim 21.

Claim 25

Compounds as recited in claim 18, wherein A is selected from the group consisting of H-Met-Glu-His, desamino-Met-Glu-His, H-Met-Ala-Ala, and desamino-Met-Ala-Ala.

Claim 26

Compounds as recited in claim 18, wherein A is selected from the sulfoxides or sulfones of H-Met-Glu-His, desamino-Met-Glu-His, H-Met-Ala-Ala, and desamino-Met-Ala-Ala.

Claim 27

Compounds as recited in claim 18, wherein the second lysine group is in its D-form.

Claim 28

The compound as recited in claim 25, wherein A is H-Met-Ala-Ala, B is Phe, and X is NH 2 .

Claim 29

The compound as recited in claim 25, wherein A is H-met(→ O 2 )-Ala-Ala, B is Phe, and X is NH 2 .

Claim 30

The compound as recited in claim 25, wherein A is H-Met(→ O)-Ala-Ala, B is Phe, and X is NH 2 .

Claim 31

The compound as recited in claim 25, wherein A is H-Met(→ O 2 )-Glu-His, B is Phe, and X is NH 2 .

Claim 32

The compound as recited in claim 25, wherein A is H-Met(→ O 2 )-Ala-Ala, B is Ala, and X is NH 2 .

Claim 33

The compound as recited in claim 25, wherein A is desamino-Met(→ O 2 )-Ala-Ala, B is Phe, and X is NH 2 .

Claim 34

The compound as recited in claim 25, wherein A is desamino-Met(→ O)-Ala-Ala, B is Phe, and X is NH 2 .

Claim 35

The compound as recited in claim 25, wherein A is H-Met(→ O 2 )-Glu-His, B is Phe, and X is NH 2 .

Claim 36

A composition of matter as recited in claim 18, wherein A is a peptide consisting of two or three amino acids selected from the group consisting of Met, Met (→ O), Met (→ O 2 ), Glu, Ser, His, Phe, Arg, Lys, Trp, Gly, Val, Leu, Ala, Ileu, β-Ala, (α-Me)Ala, Tyr and Thr.